An evidence-based summary of insulin analogues

P and T

Volumn 30, Issue 2, 2005, Pages 112-122

  Fedutes, Bethany A ^a,b,c   Donihi, Amy Calabrese ^a,d   Culley, Colleen M ^a,d   McCreery, Bryan J ^a,b,d   Ansani, Nicole T ^e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Rite Aid   (United States)

^d Dept of Pharmacy and Therapeutics ^*

^e PFIZER

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIDIABETIC AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ISONIAZID; MONOAMINE OXIDASE INHIBITOR; NICOTINIC ACID; PHENOTHIAZINE DERIVATIVE; SALICYLIC ACID DERIVATIVE; SULFANILAMIDE;

ALLERGIC REACTION; BLOOD GLUCOSE MONITORING; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; GLUCOSE METABOLISM; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SYNTHESIS; LIPODYSTROPHY; PANCREAS ISLET BETA CELL; PHARMACODYNAMICS; PRURITUS; RASH; REVIEW;

EID: 13744259499     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Iltz JL, White JR. Current diabetes medication and the multi-risk patient. Clin Pharm Newswatch 1999;6:1-6.
2. American Association of Clinical Endocrinologists, American College of Endocrinology. Medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management. 2000 update. Endocr Pract 2000;6:42-79.
3. American Diabetes Association (ADA). Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917-932.
4. American Diabetes Association (ADA). ADA 2004 Clinical Practice Recommendations. Diabetes Care 2004;27:S1-S143.
5. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
6. United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 2: A 6-year randomized, controlled, trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128:165-175.
7. Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-389.
8. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Hardman HG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. New York: McGraw-Hill; 2001:1679-1714.
9. NovoLog® (insulin aspart) package insert Princeton, NJ: Novo Nordisk, December 2002.
10. Humalog® (insulin lispro) package insert. Indianapolis, IN: Eli Lilly, May 2002.
11. Lantus® (insulin glargine) package insert. Kansas City, MO: Avenus, May 2003.
12. Bolli GB, Owens DR. Insulin glargine. Lancet 2000;356:443-445.
13. Buse J. Insulin glargine (HOE 901): First responsibilities: Understanding the data and ensuring safety. Diabetes Care 2000;23:576-578.
14. Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE 901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-649.
15. Frohnauer MK, Woodworth JR, Anderson JH. Graphical human insulin time-activity profiles using standardized definitions. Diabetes Technol Ther 2001;3:419-429.
16. Kahn CR, Shechter Y. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics, 8th ed. New York: McGraw-Hill; 1993:1476.
17. Oki JC, Isley WL Diabetes mellitus. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: A Pathophysiologic Approach, 5th ed. New York: McGraw-Hill; 2002:1342.
18. Holleman F, Hoekstra JBL. Drug therapy: Insulin lispro. N Engl J Med 1997;337:176-183.
19. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-2148.
20. Hedman CA, Lindstrom T Arnqvist HJ. Direct comparison of insulin lispro and aspart shows differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes 2001;24:1120-1121.
21. Lindstrom T, Hedman C, Arnqvist HJ. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs. Diabetes 2002;25:1049-1054.
22. Plank J, Wutte A, Brunner G, et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002;25:2053-2057.
23. Von Mach MA, Brinkmann C, Hansen T, et al. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp Clin Endocrinol Diabetes 2002; 110:416-419.
24. 125I-labeled insulin glargine (HOE 901) in healthy men. Diabetes Care 2000;23:813-819.
25. Home PD, Lindholm A, Hylleberg B, et al. Improved glycemic control with insulin aspart. Diabetes Care 1998;21:1904-1909.
26. Lindholm A, McEwen J, Riis A. Improved postprandial glycemic control with insulin aspart. Diabetes Care 1999;22:801-805.
27. Brunner GA, Hirschberger G, Sendlhofer A, et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med 2000;17:371-375.
28. Home PD, Lindholm A, Riss A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: A randomized controlled trial. Diabet Med 2000; 17:762-770.
29. Raskin P, Guthrie RA, Letter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes mellitus. Diabetes Care 2000;23:583-588.
30. Tamas G, Marre M, Astorga R, et al. Glycemic control in type 1 diabetic patients using optimized insulin aspart or human insulin in a randomized multinational study. Diabetes Res Clin Pract 2001;54:105-114.
31. DeVries JH, Lindholm A, Jacobsen JL, et al. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with type 1 diabetes. Diabet Med 2003;20:312-318.
32. Rosenfalck AM, Thorsby P, Kjems L, et al. Improved postprandial glycemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000;37:41-46.
33. Raskin P, Mcgill J, Kilo C, et al. Human insulin analogue (insulin aspart, IAsp) is comparable to human insulin (HI) in type 2 diabetes (Abstract 355). Diabetes 1999;48:1s.
34. Bode BW, Strange P. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 2001;24:69-72.
35. Bode BW, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion. Diabetes Care 2002;25:439-444.
36. Holleman F, Schmitt H, Rottiers R, et al. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care 1997;20:1827-1832.
37. Heller SR, Amiel SA, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. Diabetes Care 1999;22:1607-1611.
38. Anderson JH, Brunelle RL, Koivisto VA. Reduction of post-prandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin analog treatment. Diabetes 1997;46:265-270.
39. United Kingdom Trial Group. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. Diabet Med 2000;17:209-214.
40. Brunelle RL, Llewelyn J, Anderson JH, et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998;21:1726-1731.
41. Anderson JH, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1997;157:1249-1255.
42. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000;23:157-162.
43. Rosenstock J, Park S, Zimmerman R Basal insulin glargine (HOE 911) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000;23:1137-1142.
44. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639-643.
45. Raskin P, Klaff L, Bergenstal R, et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666-1671.
46. Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: A 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003;26:1490-1496.
47. Lepore G, Dodesini AR, Nosari I, Trevisan R. Both continuous subcutaneous insulin infusion with a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment. Diabetes Care 2003;26:1321-1322.
48. Yki-Jarvinen H, Dressler A, Aiemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-1136.
49. Rosenstock J, Schwartz SL, Clark CM, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-636.
50. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35(3):189-196.
51. Raskin P, Park G, Zimmerman J. The effect of HOE 901 on glycemic control in type 2 diabetes (Abstract). Diabetes 1998; 47(Suppl 1):A404.
52. Matthews DR, Pfeiffer C. Comparative clinical trial of a new long-acting insulin (HOE901) vs. protamine insulin demonstrates less nocturnal hypoglycemia (Abstract). Diabetes 1998;47(Suppl 1):A0394.
53. Heinemann L. Hypoglycemia and insulin analogs: Is there a reduction in the incidence? J Diabetes Complications 1999;13:105-114.
54. McKeage K, Goa KL. Insulin glargine: A review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 2001;61:1599-1624.
55. Berger M. Safety of insulin glargine. Lancet 2000;356:2013-2014.
56. Lenhard MJ, Reeves GD. Continuous subcutaneous insulin infusion. Arch Intern Med 2001;161:2293-2300.
57. Davey P, Grainger D, MacMillan J, et al. Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach. Pharmacoeconomics 1998;13(3): 347-358.
58. Hall JA, Summers KH, Obenchain RL Cost and utilization comparisons among propensity score-matched insulin lispro and regular insulin users. J Manag Care Pharm 2003;9(3):263-268.
59. Drug prices & information. Available at: www.drugstore.com. Accessed February 1, 2004
60. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med 2003;20:886-898.
61. FDC Reports, Inc. Available at: www.ndapipeline.com. Accessed February 4, 2004.
62. Kordella T. The future of insulin. Diabetes Forecast 2003;63-66. Available at www.diabetes.org. Accessed January 10, 2005.
63. FDC Reports. Novo detemir "approvable letter." Pink Sheet 2003;65(41):44.